Literature DB >> 20978738

Delayed onset of hyperglycaemia in a mouse model with impaired glucagon secretion demonstrates that dysregulated glucagon secretion promotes hyperglycaemia and type 2 diabetes.

N Gustavsson1, T Seah, Y Lao, G K Radda, T C Südhof, W Han.   

Abstract

AIMS/HYPOTHESIS: Type 2 diabetes is caused by relative deficiency of insulin secretion and is associated with dysregulation of glucagon secretion during the late stage of diabetes development. Like insulin secretion from beta cells, glucagon secretion is dependent on calcium signals and a calcium sensing protein, synaptotagmin-7. In this study, we tested the relative contribution of dysregulated glucagon secretion and reduced insulin release in the development of hyperglycaemia and type 2 diabetes by using synaptotagmin-7 knockout (KO) mice, which exhibit glucose intolerance, reduced insulin secretion and nearly abolished Ca(2+)-stimulated glucagon secretion.
METHODS: We fed the synaptotagmin-7 KO and control mice with a high-fat diet (HFD) for 14 weeks, and compared their body weight, glucose levels, glucose and insulin tolerance, and insulin and glucagon secretion.
RESULTS: On the HFD, synaptotagmin-7 KO mice showed progressive impairment of glucose tolerance and insulin secretion, along with continued maintenance of a low glucagon level. The control mice were less affected in terms of glucose intolerance, and showed enhanced insulin secretion with a concurrent increase in glucagon levels. Unexpectedly, after 14 weeks of HFD feeding, only the control mice displayed resting hyperglycaemia, whereas in synaptotagmin-7 KO mice defective insulin secretion and reduced insulin sensitivity were not sufficient to cause hyperglycaemia in the absence of enhanced glucagon secretion. CONCLUSIONS/
INTERPRETATION: Our data uncover a previously overlooked role of dysregulated glucagon secretion in promoting hyperglycaemia and the ensuing diabetes, and strongly suggest maintenance of adequate regulation of glucagon secretion as an important therapeutic target in addition to the preservation of beta cell function and mass in the prevention and treatment of diabetes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20978738     DOI: 10.1007/s00125-010-1950-2

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  27 in total

Review 1.  Molecular defects in insulin secretion in type-2 diabetes.

Authors:  Frances M Ashcroft; Patrik Rorsman
Journal:  Rev Endocr Metab Disord       Date:  2004-05       Impact factor: 6.514

2.  The insulin receptor talks to glucagon?

Authors:  Jesper Gromada; Alokesh Duttaroy; Patrik Rorsman
Journal:  Cell Metab       Date:  2009-04       Impact factor: 27.287

Review 3.  The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications.

Authors:  Beth Elaine Dunning; John E Gerich
Journal:  Endocr Rev       Date:  2007-04-04       Impact factor: 19.871

Review 4.  Clinical importance of insulin secretion and its interaction with insulin resistance in the treatment of type 2 diabetes mellitus and its complications.

Authors:  D Porte
Journal:  Diabetes Metab Res Rev       Date:  2001 May-Jun       Impact factor: 4.876

5.  Beta-cell secretory products activate alpha-cell ATP-dependent potassium channels to inhibit glucagon release.

Authors:  Isobel Franklin; Jesper Gromada; Asllan Gjinovci; Sten Theander; Claes B Wollheim
Journal:  Diabetes       Date:  2005-06       Impact factor: 9.461

6.  Synaptotagmin-7 is a principal Ca2+ sensor for Ca2+ -induced glucagon exocytosis in pancreas.

Authors:  Natalia Gustavsson; Shun-Hui Wei; Dong Nhut Hoang; Ye Lao; Quan Zhang; George K Radda; Patrik Rorsman; Thomas C Südhof; Weiping Han
Journal:  J Physiol       Date:  2009-01-26       Impact factor: 5.182

Review 7.  Calcium-sensing beyond neurotransmitters: functions of synaptotagmins in neuroendocrine and endocrine secretion.

Authors:  Natalia Gustavsson; Weiping Han
Journal:  Biosci Rep       Date:  2009-08       Impact factor: 3.840

8.  Impaired insulin secretion and glucose intolerance in synaptotagmin-7 null mutant mice.

Authors:  Natalia Gustavsson; Ye Lao; Anton Maximov; Jen-Chieh Chuang; Elena Kostromina; Joyce J Repa; Cai Li; George K Radda; Thomas C Südhof; Weiping Han
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-28       Impact factor: 11.205

9.  Genetic analysis of synaptotagmin-7 function in synaptic vesicle exocytosis.

Authors:  Anton Maximov; Ye Lao; Hongmei Li; Xiaocheng Chen; Josep Rizo; Jakob B Sørensen; Thomas C Südhof
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-28       Impact factor: 11.205

10.  Glucose inhibition of glucagon secretion from rat alpha-cells is mediated by GABA released from neighboring beta-cells.

Authors:  Anna Wendt; Bryndis Birnir; Karsten Buschard; Jesper Gromada; Albert Salehi; Sabine Sewing; Patrik Rorsman; Matthias Braun
Journal:  Diabetes       Date:  2004-04       Impact factor: 9.461

View more
  3 in total

1.  Hyperglucagonemia precedes a decline in insulin secretion and causes hyperglycemia in chronically glucose-infused rats.

Authors:  Rachel A Jamison; Romana Stark; Jianying Dong; Shin Yonemitsu; Dongyan Zhang; Gerald I Shulman; Richard G Kibbey
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-08-23       Impact factor: 4.310

2.  Increased lipolysis and energy expenditure in a mouse model with severely impaired glucagon secretion.

Authors:  Phing-How Lou; Natalia Gustavsson; Yue Wang; George K Radda; Weiping Han
Journal:  PLoS One       Date:  2011-10-27       Impact factor: 3.240

3.  Increased biogenesis of glucagon-containing secretory granules and glucagon secretion in BIG3-knockout mice.

Authors:  Hongyu Li; Tao Liu; Joy Lim; Natalia V Gounko; Wanjin Hong; Weiping Han
Journal:  Mol Metab       Date:  2015-01-09       Impact factor: 7.422

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.